Get 40% Off
🤯 This Tech Portfolio is up 29% YTD! Join Now to Get April’s Top PicksGet The Picks – Just 99 USD

European shares open higher after record highs in Asia, Wall Street

Published 12/09/2017, 09:40
Updated 12/09/2017, 09:40
© Reuters. The German share price index, DAX board, is seen at the stock exchange in Frankfurt

© Reuters. The German share price index, DAX board, is seen at the stock exchange in Frankfurt

By Julien Ponthus

LONDON (Reuters) - European bourses continued their relief rally, opening higher on Tuesday after stock markets in Asia and in the United States hit record highs as worries about Hurricane Irma and North Korea’s nuclear standoff eased.

All major trading centres and most sectors traded in positive territory as the pan-European STOXX 600 (STOXX) rose 0.3 percent, although some investors questioned how sustainable current markets levels are.

"Whether that equity reaction is Panglossian complacency or a sign of wonderful underlying fundamentals remains open to question," ING wrote in a morning note, adding that "even Category 5 storms can now be added to the list of things that 'Don't Really Matter'".

Financial stocks were yet again among the top performers, with financial services (SXFP) and banking (SX7P) respectively up 0.7 and 0.6 percent.

Insurance firms (SXIP), which fuelled Europe's rise on Monday with a roughly 2 percent jump, were again in positive territory, edging up 0.3 percent.

"The structure of today's open is typically 'risk-on'", said Pierre Martin, a senior sales trader at Saxo Bank, noting that the positive trend for banking stocks or automobile shares showed investors' moods were off geopolitical and climate worries and back to more positive corporate and macroeconomic news.

Volkswagen (DE:VOWG_p) was up 0.5 percent after announcing a 20 billion euro plan on Monday to develop zero-emission vehicles and other constructors were also gaining ground, such as Peugeot (PA:PEUP) which topped France's blue chip CAC 40 (FCHI) index with a 1.5% rise.

Novartis (S:NOVN) gained 0.6 percent as it reported that its biosimilar rituximab to treat blood cancers and immunological diseases such as rheumatoid arthritis was accepted for review by the U.S. Food and Drug Administration (FDA).

Among losers, French veterinarian pharmaceutical company Virbac (PA:VIRB) sank 11.7 percent after cutting its full-year outlook.

© Reuters. The German share price index, DAX board, is seen at the stock exchange in Frankfurt

British home builders were also under pressure with Taylor Wimpey (L:TW) losing 2.8 percent or Barrat Development 2.4 percent after a report highlighted risks to the sector, a trader said.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.